BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240604
DTEND;VALUE=DATE:20240607
DTSTAMP:20260515T181749
CREATED:20240219T105830Z
LAST-MODIFIED:20240219T105830Z
UID:38732-1717459200-1717718399@www.pharmajournalist.com
SUMMARY:Computational RNA Design & Delivery Summit
DESCRIPTION:AI and computational science are revolutionizing the field of RNA therapeutic discovery\, which is empowering biopharma companies to harness the potential of this technology. Join the conversation at the world’s first industry-dedicated Computational RNA Design & Delivery Summit taking place in Boston this June 4 – 6 2024. \nHear what industry pioneers from Sanofi\, Moderna\, Nava Therapeutics\, Nutcracker Therapeutics\, and more have to say\, and deep dive into harnessing AI\, Machine learning\, deep neural networks\, and predictive algorithms for RNA design and delivery to scale and accelerate novel\, cost-effective RNA-based therapeutics. \nHere’s a snapshot of the speaker faculty: \n\nMihir Mektar\, Principal Scientist\, Moderna\nSarah Spencer\, Senior Expert II Data Science\, Novartis\nBenjamin Mead\, Principal Data Scientist\, Nava Therapeutics\nDinghai Zheng\, Machine Learning Senior Scientist\, Sanofi\nEvan McCartney-Melstad\, Director of Bioinformatics\, Nutcracker Therapeutics\nKelly Brock\, Senior Computational Biologist\, Kernal Biologics\n\nThis exclusive meeting has been designed with you in mind! Join 80+ data science\, computational biology/chemistry\, bioinformatic\, and delivery experts to accelerate discovery of your mRNA\, RNAi\, and tRNA modalities and innovate the delivery of these modalities beyond the liver by deep-diving into LNP\, peptide-based\, and AAV delivery chemistry. \nBook your place now\, early birds are still available!
URL:http://www.pharmajournalist.com/event/computational-rna-design-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240613
DTSTAMP:20260515T181749
CREATED:20240215T112047Z
LAST-MODIFIED:20240215T112047Z
UID:38716-1717977600-1718236799@www.pharmajournalist.com
SUMMARY:6th Allogeneic Cell Therapies Summit
DESCRIPTION:The entire cell therapy field is experiencing a shift towards allogeneic platforms as the potential to achieve a truly off-the-shelf\, universal\, and efficacious cell therapy offers great advantages such as reduced cost\, production and patient accessibility compared to its autologous counterparts. \nPlacing a spotlight on what has been deemed the ‘future of cell therapy’\, the 6th Annual Allogeneic Cell Therapies Summit returns to Boston this June as the leading industry focused meeting dedicated to accelerating the safety\, durability and clinical translation of off-the-shelf therapies to deliver affordable and accessible treatments for patients in critical need. \nAcross a jam-packed agenda consisting of 60+ hours of content\, 3 in-depth tracks\, 1 Investor & Business Development Focus Day\, 1 Beyond Oncology Bootcamp Day and more; our 50+ expert speakers will lead you and your peers in discussions that will help to transform universal cell therapies for patients across the globe. \nLearn more here: https://ter.li/aetc0d
URL:http://www.pharmajournalist.com/event/6th-allogeneic-cell-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240612
DTSTAMP:20260515T181749
CREATED:20240502T125908Z
LAST-MODIFIED:20240502T125908Z
UID:39043-1717977600-1718150399@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes West Coast
DESCRIPTION:SAE Media Group’s 8th Annual Pre-Filled Syringes West Coast Conference will be back for 2024 in the West Coast to bring together device developers\, biotech and big pharma. This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \n \nAs part of SAE’s leading injectable drug delivery conferences this is a must attend event; not only will the conference bring you key insights to enhance your drug device portfolio\, but it will also give you the opportunity to network with key industry players. We hope to welcome you in June 2024! \nWhat will you gain? \n\nEngage in discussions on evolving EU and US regulations as well as reviewing the latest FDA guidance on human factors and drawing insights from successful notified body opinions for streamlined regulatory compliance.\nGain insight into advancements in large volume drug delivery devices with a case study from Halozyme and a panel discussion assessing key considerations\, benefits and barriers of such devices for stakeholders including patients\, HCPs and pharma companies.\nDelve into comprehensive strategies for maximizing combination product manufacturing and effectively managing your product’s lifecycle with key insights from GSK and Merck\nAcquire insights into human factors best practices from AbbVie and Regeneron\, and discover ways to effectively apply testing and validation approaches for combination products.\nExplore collaborative opportunities to advance innovation in the injectables field and gain insight into the latest technology updates and challenges these pose such as leaching in electro-mechanical devices.
URL:http://www.pharmajournalist.com/event/pre-filled-syringes-west-coast-2024/
LOCATION:SAN DIEGO MARRIOTT LA JOLLA\, 4240 La Jolla Village Drive\, La Jolla\, San Diego\, CA\, 92037\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:EVENTS@SAEMEDIAGROUP.COM
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240611
DTEND;VALUE=DATE:20240614
DTSTAMP:20260515T181749
CREATED:20240208T112624Z
LAST-MODIFIED:20240208T112624Z
UID:38638-1718064000-1718323199@www.pharmajournalist.com
SUMMARY:3rd Process Development for Cell Therapies Summit
DESCRIPTION:Driving Process Robustness\, Scalability\, Speed & Affordability \nIn the dynamic cell therapy landscape\, where financial challenges continue to prevail\, the emphasis on innovative process development becomes pivotal. Now\, more than ever\, there’s a heightened demand for cost-effective solutions that bolster scalability and expedite development timelines. \nWelcome to the 3rd Process Development for Cell Therapies Summit\, your paramount gathering dedicated to advancing process robustness\, scalability\, speed\, and affordability. This ensures the rapid advancement of highly efficacious products through clinical trials\, securing a market-ready status with competitive commercial viability. \nWhether you’re on the brink of IND or gearing up for BLA submission\, this gathering of brilliant minds offers an unparalleled opportunity to glean insights form organizations like BMS\, Beam Therapeutics\, 2seventy Bio\, Takeda\, Century Therapeutics\, AstraZeneca\, and more! \nSeize this opportunity to connect with technical experts united in the goal of streamlining process development. Through the sharing of best practices and pre-competitive insights\, let’s collectively drive the streamlined development of consistent\, scalable\, and cost-effective autologous and allogeneic cell therapies. Together\, we can shape the future of cell therapy! \nTo know more visit: https://ter.li/ixkr7z
URL:http://www.pharmajournalist.com/event/3rd-process-development-for-cell-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240611
DTEND;VALUE=DATE:20240614
DTSTAMP:20260515T181749
CREATED:20240208T113943Z
LAST-MODIFIED:20240222T125925Z
UID:38641-1718064000-1718323199@www.pharmajournalist.com
SUMMARY:Structure-Based Drug Design Summit
DESCRIPTION:Harnessing Integrative Structural Biology Techniques Including NMR\, X-Ray Crystallography\, Cryo-EM\, & Cryo-ET to Determine 3D Structures of Pharmacologically Relevant Targets & Propel Drug Design \nHave you heard the boom created by Cryo-EM? Drug development has been shaken up with the application of Cryo-EM\, accelerating and increasing the rate of success of protein targeting by identifying new ways to treat diseases with greater sensitivity and efficiency in the study of 3D structures. Structural biologists\, medicinal chemists\, and computational chemists need to assess the experimental methods by sharing case study presentations to streamline\, rationalize\, and optimize drug design. \nThe inaugural Structure-Based Drug Design Summit  is your opportunity to assess the resolution and speed of the techniques in the toolbox to answer structural biology questions for drug design\, assess the gaps\, and implement newer techniques for increased specificity and precision \nSharing cutting-edge structural biology methods and applications\, including harnessing Cryo-EM and Cryo-ET to visualize protein interactions\, structure-based methods as a package of techniques to study integrated biological systems\, and incorporating computational methods as a predictive tool for structures; this is a unique opportunity to come together and rationalize drug design by understanding the 3D structure of proteins. Join 50+ industry scientists to delve into 3D protein structure determination using NMR\, X-Ray Crystallography\, Cryo-EM\, and Cryo-ET\, to improve resolution and efficiency and rationalize drug development. \nRevolutionize the way drugs are discovered and developed to lead to newer and more effective therapeutics for a wide range of diseases\, build the complete 3D picture\, and go after undruggable targets.
URL:http://www.pharmajournalist.com/event/structure-based-drug-design-summit/
LOCATION:Embassy Suites by Hilton Boston at Logan Airport\, 207 Porter St\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240611
DTEND;VALUE=DATE:20240614
DTSTAMP:20260515T181749
CREATED:20240321T115006Z
LAST-MODIFIED:20240321T115126Z
UID:38904-1718064000-1718323199@www.pharmajournalist.com
SUMMARY:6th Age-Related Disease Therapeutics Summit
DESCRIPTION:The 6th Age-Related Disease Therapeutics Summit is returning to San Francisco in June\, with 60+ participants including Eli Lilly\, Takeda\, and Turn Biosciences to dive deep into breakthroughs in cellular programming\, senolytic pathways\, and epigenetic effects. Explore biomarkers\, navigate regulations\, and foster collaborations for pipeline support and commercialization. \nThis is your definitive age-related disease therapeutics forum to gain unparalleled competitive intelligence\, scientific advancements and form meaningful partnerships to solve humankind’s fundamental problem.
URL:http://www.pharmajournalist.com/event/6th-age-related-disease-therapeutics-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240612
DTEND;VALUE=DATE:20240615
DTSTAMP:20260515T181749
CREATED:20240410T111557Z
LAST-MODIFIED:20240411T111540Z
UID:38976-1718150400-1718409599@www.pharmajournalist.com
SUMMARY:4th Next Generation Gene Therapy Vectors Summit
DESCRIPTION:Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14\, Boston) \nAs a recent whitepaper by the Alliance for Regenerative Medicine cites capsid engineering and disruptive delivery platforms as key emerging technologies in the CGT space\, drug developers are heavily investing in finding and optimizing the safety\, efficacy\, and predictability of delivery platforms. \nThis is 2024’s only meeting covering the latest advances and innovations in vector development for gene therapies\, uniting 90+ R&D and business development leaders to advance cutting-edge delivery platforms into the clinic. Data-driven talks\, expert panels\, and interactive group discussions led by 25+ industry experts will provide you with the ‘latest and greatest’ in both disruptive viral and non-viral vectors. \nJoin us to gain actionable insights in how to enable targeted gene delivery\, reduce immunogenicity & toxicity\, enhance downstream manufacturability\, expand packaging capabilities\, and secure funding and investment for your own vector platform. \nWant to learn more? Check out the event guide here https://ter.li/nnkbb3
URL:http://www.pharmajournalist.com/event/4th-next-generation-gene-therapy-vectors-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240619
DTEND;VALUE=DATE:20240621
DTSTAMP:20260515T181749
CREATED:20240321T120430Z
LAST-MODIFIED:20240321T120754Z
UID:38919-1718755200-1718927999@www.pharmajournalist.com
SUMMARY:World CDx Regulatory Affairs & Policy Summit
DESCRIPTION:The highly anticipated World CDx Regulatory Affairs & Policy Summit\, is set to debut in Boston from June 19-20\, 2024. \nFrom tackling the complexities of LDT regulation and navigating the IVDR maze to understanding reimbursement dynamics\, this groundbreaking meeting promises to provide clarity and harmonization in the realm of CDx regulation. Attendance is FREE for drug developers and academics\, join us to maintain your clinical momentum\, streamline submissions\, overcome regulatory bottlenecks\, and improve patient access to companion diagnostics. \nWorld Class speakers you have the opportunity to learn from: \n\nVihanga Pahalawatta\, Director – Regulatory Affairs Companion Diagnostics\, AbbVie\nAndrea Renninger\, Senior Director – CDx Regulatory Affairs\, Daiichi Sankyo\nClaudia Dollins\, Vice President – Global Regulatory Affairs\, GSK\nDebra Rasmussen\, Senior Director – Global Regulatory Affairs\, Johnson & Johnson\nDun Liang – Executive Director\, Regulatory Affairs\, CDx\, Loxo@Lilly\nSiddhartha Mathur – Executive Director – Regulatory Affairs\, Merck\nQing Li\, Director – Pathology\, clinical development\, Oncology\, Moderna\nJai Pandey\, Global Head – Device Regulatory for In Vitro Diagnostics & Companion Diagnostics\, Digital Health\, Sanofi\n\nThis summit is poised to bring together key stakeholders\, including Directors\, VPs\, and SVPs in Regulation\, Policy\, Reimbursement\, Digital Health\, and Companion Diagnostics from leading companies as well as regulatory experts\, payers\, and developers to bridge the gap with clinical practice and ease regulatory pressures. Download the brochure or secure your free place now!
URL:http://www.pharmajournalist.com/event/world-cdx-regulatory-affairs-policy-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240625
DTEND;VALUE=DATE:20240628
DTSTAMP:20260515T181749
CREATED:20240223T112318Z
LAST-MODIFIED:20240223T112353Z
UID:38757-1719273600-1719532799@www.pharmajournalist.com
SUMMARY:Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Cell and gene therapies are revolutionizing healthcare\, offering promising solutions from curative treatments to long-term remission rates. As these treatments enter the market\, ensuring fair access while addressing coverage and payment complexities becomes paramount. \n  Introducing the inaugural Cell & Gene Therapy Pricing & Reimbursement Summit. Biotech\, pharma\, physicians\, healthcare providers\, and regulatory and government agencies will unite to address key issues such as the impact of regulatory acts\, implementing pricing models\, and collaborating on enhanced reimbursement strategies\, aiming to expedite the availability of these advanced therapies to patients. \nWith the recent approval of Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics\, and Lyfgenia by bluebird bio; significant strides in healthcare have been made\, offering groundbreaking treatments with transformative potential\, yet presenting substantial cost challenges. The Inflation Reduction Act and new Cell and Gene Therapy (CGT) Access Model aim to address these cost concerns by proposing innovative pricing models and reimbursement strategies to ensure affordability and widespread access to these life-changing therapies. \n Join us this June to discuss the impacts of this legislation and together\, we will optimize patient access and propel the success of commercial cell and gene therapy launches. \nSee the full agenda here: https://ter.li/d1rn7b
URL:http://www.pharmajournalist.com/event/cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240625
DTEND;VALUE=DATE:20240628
DTSTAMP:20260515T181749
CREATED:20240321T120048Z
LAST-MODIFIED:20240321T120048Z
UID:38913-1719273600-1719532799@www.pharmajournalist.com
SUMMARY:2nd mRNA Quality Control & Compliance Summit
DESCRIPTION:Regulatory guidelines and existing protocols to govern aspects of mRNA quality during development and manufacturing are still evolving\, creating a lack of clarity and consensus amongst the mRNA community. \nWithout a clear path forward\, drug developers risk comprising product quality\, safety and efficacy\, and so the 2nd mRNA Quality Control & Compliance Summit is back to Boston this June as the sole industry-centred forum dedicated to showcasing data and discussions on mRNA compliance and optimized documentation\, ensuring streamlined approval for mRNA therapeutics and vaccines! \nReuniting industry experts in quality control\, quality assurance\, analytical development\, and CMC\, this forum aims to navigate regulatory guidelines and identify tangible best practices towards optimized documentation\, discuss verification processes for platform methods and review method validation used to evaluate critical vaccine qualities\, all towards safeguarding faster mRNA drug approvals in line with regulatory expectations. \nDownload the free brochure or book your place now\, early birds are still available!
URL:http://www.pharmajournalist.com/event/2nd-mrna-quality-control-compliance-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR